Huge demand for ASEP's sepsis diagnostic technology Asep Medical Holdings Inc ( $ASEP.C ) is a biotech company that is in the clinical trial phases of testing its sepsis detection technology.
In 2017 alone sepsis occurred in 49 MILLION people. Currently, antibiotics are the go-to treatment for sepsis but for 23% of these patients, antibiotics fail. This contributes to the 11 million deaths caused by sepsis yearly.
$ASEP's tech includes a novel diagnostic tool that detects the dysfunctional immune response that underlies the most severe forms of sepsis. This tech will facilitate early sepsis detection which will allow doctors to make better informed life-saving decisions which will add to the efficacy of antibiotics.
The infection rate and death toll alone illustrates the demand for $ASEP's sepsis tech.
Clinical testing is already underway for the sepsis detection tech and the company intends to file for regulatory approval within the next 6-9 months which could be a huge catalyst for the company.
Right now $ASEP is trading at $0.50 (stable today)
https://asepmedical.com/technologies/diagnostic/